David Roodman

4.3k total citations · 1 hit paper
33 papers, 2.3k citations indexed

About

David Roodman is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, David Roodman has authored 33 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 18 papers in Hematology and 17 papers in Oncology. Recurrent topics in David Roodman's work include Multiple Myeloma Research and Treatments (18 papers), Bone health and treatments (9 papers) and Bone Metabolism and Diseases (6 papers). David Roodman is often cited by papers focused on Multiple Myeloma Research and Treatments (18 papers), Bone health and treatments (9 papers) and Bone Metabolism and Diseases (6 papers). David Roodman collaborates with scholars based in United States, Germany and Switzerland. David Roodman's co-authors include Gregory R. Mundy, Brendan F. Boyce, Toshiyuki Yoneda, D. E. Hughes, Akira Sasaki, Kenneth R. Wright, Johannes Pfeilschifter, Andrew Bird, Chantal Chenu and Robert A. Kyle and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Cell Biology and Blood.

In The Last Decade

David Roodman

32 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

1995 846 citations D. E. Hughes, Kenneth R. Wright et al. Journal of Bone and Mineral Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Roodman United States	13	1.4k	1.0k	569	430	278	33	2.3k
Samantha Pozzi Italy	27	1.1k 0.8×	853 0.8×	129 0.2×	536 1.2×	120 0.4×	91	2.3k
C M Shipman United Kingdom	14	1.6k 1.1×	774 0.8×	344 0.6×	481 1.1×	533 1.9×	31	2.0k
Bertha Frisch Israel	26	472 0.3×	529 0.5×	388 0.7×	841 2.0×	105 0.4×	72	2.2k
Marc Baud’huin France	26	706 0.5×	1.2k 1.1×	171 0.3×	205 0.5×	77 0.3×	50	2.1k
Jan Elliott Australia	15	1.4k 1.0×	1.8k 1.8×	337 0.6×	109 0.3×	121 0.4×	18	2.4k
Vincent Castronovo Belgium	21	1.1k 0.8×	930 0.9×	419 0.7×	79 0.2×	418 1.5×	28	2.3k
Mark Tometsko United States	13	2.6k 1.8×	3.0k 3.0×	560 1.0×	131 0.3×	222 0.8×	18	4.3k
Julie C. Frith United Kingdom	13	2.3k 1.6×	928 0.9×	1.1k 2.0×	70 0.2×	659 2.4×	17	2.9k
Rowena D. Devlin United States	17	696 0.5×	830 0.8×	251 0.4×	261 0.6×	50 0.2×	20	1.6k
Magne Børset Norway	38	1.6k 1.1×	2.3k 2.2×	106 0.2×	1.9k 4.4×	155 0.6×	107	4.3k

Countries citing papers authored by David Roodman

Since Specialization

Citations

This map shows the geographic impact of David Roodman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Roodman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Roodman more than expected).

Fields of papers citing papers by David Roodman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Roodman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Roodman. The network helps show where David Roodman may publish in the future.

Co-authorship network of co-authors of David Roodman

This figure shows the co-authorship network connecting the top 25 collaborators of David Roodman. A scholar is included among the top collaborators of David Roodman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Roodman. David Roodman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meo, Francesco Di, Rujin Cheng, Christina Y. Yu, et al.. (2023). A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Reports Medicine. 4(7). 101110–101110. 17 indexed citations

Meo, Francesco Di, Christina Y. Yu, Rujin Cheng, et al.. (2022). A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma. Blood. 140(Supplement 1). 671–672. 2 indexed citations

Meo, Francesco Di, Rujin Cheng, Christina Y. Yu, et al.. (2022). A Target Discovery Pipeline Identified ILT3 as a Target for Immunotherapy of Multiple Myeloma. SSRN Electronic Journal. 5 indexed citations

Kyriakou, Charalampia, Sean Molloy, Frank D. Vrionis, et al.. (2019). The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer Journal. 9(3). 27–27. 57 indexed citations

Kovács, János, Chong Li, Qin Yang, et al.. (2011). Autophagy promotes T-cell survival through degradation of proteins of the cell death machinery. Cell Death and Differentiation. 19(1). 144–152. 182 indexed citations

Munshi, Nikhil C., Suman Kambhampati, Michal G. Rose, et al.. (2011). Once a Week Bortezomib with Dexamethasone Is Effective with Limited Toxicity in Newly Diagnosed Multiple Myeloma Patients with Older Age and Co-Morbidities,. Blood. 118(21). 3964–3964.

Teramachi, Jumpei, Jolene J. Windle, David Roodman, & Noriyoshi Kurihara. (2010). The ZZ Domain of Sequestosome-1/p62 Plays An Important Role In Stromal Cell Support of Myeloma Cell Growth and Osteoclast Formation. Blood. 116(21). 128–128. 3 indexed citations

Hussein, M. A., Frank D. Vrionis, Robert D. Allison, et al.. (2008). The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia. 22(8). 1479–1484. 46 indexed citations

Hiruma, Yuko, Noriyoshi Kurihara, Diane F. Jelinek, & David Roodman. (2008). Increased Signaling through p62 in the Marrow Microenvironment Increases Myeloma Cell Growth and Osteoclast Formation. Blood. 112(11). 642–642. 1 indexed citations

10.

Grant, Steven, Daniel M. Sullivan, David Roodman, et al.. (2008). Phase I Trial of Bortezomib (NSC 681239) and Flavopiridol (NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms.. Blood. 112(11). 1573–1573. 4 indexed citations

11.

Kyle, Robert A., Gary C. Yee, Mark R. Somerfield, et al.. (2007). American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma. Journal of Clinical Oncology. 25(17). 2464–2472. 295 indexed citations

12.

Roodman, David. (2007). E06-01: Pathogenesis of lung cancer bone metastasis. Journal of Thoracic Oncology. 2(8). S231–S231. 2 indexed citations

13.

Noonan, Kimberly, et al.. (2007). Th-17 Lymphocytes, Not Regulatory T Cells, Mediate Immune Regulation of Bone Marrow Infiltrating Lymphocytes and Induce Osteoclast Activation in Multiple Myeloma.. Blood. 110(11). 811–811. 1 indexed citations

14.

Feng, Rentian, Ana B. Oton, Kenneth D. Patrene, et al.. (2006). Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple Myeloma Growth In Vitro and In Vivo.. Blood. 108(11). 507–507. 4 indexed citations

15.

Masih‐Khan, Esther, Suzanne Trudel, Carla Heise, et al.. (2006). MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood. 108(10). 3465–3471. 54 indexed citations

16.

Kurihara, Noriyoshi, Yuko Hiruma, Jolene J. Windle, et al.. (2006). Targeting p62 in Marrow Stromal Cells Is Effective at Inhibiting Myeloma Cell Growth.. Blood. 108(11). 513–513. 2 indexed citations

17.

Kurihara, Noriyoshi, Tadashi Honjo, Judy M. Anderson, et al.. (2005). Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 107(8). 3098–3105. 114 indexed citations

18.

Mbalaviele, Gabriel, Riko Nishimura, Maria Niewolna, et al.. (1998). Cadherin-6 Mediates the Heterotypic Interactions between the Hemopoietic Osteoclast Cell Lineage and Stromal Cells in a Murine Model of Osteoclast Differentiation. The Journal of Cell Biology. 141(6). 1467–1476. 40 indexed citations

19.

Dallas, Mark, et al.. (1995). Use of an in vivo model to determine the effects of interleukin-1 on cells at different stages in the osteoclast lineage. Journal of Bone and Mineral Research. 10(2). 295–301. 41 indexed citations

20.

Hughes, D. E., Kenneth R. Wright, Akira Sasaki, et al.. (1995). Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. Journal of Bone and Mineral Research. 10(10). 1478–1487. 846 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact